Quality of life, clinical characteristics and treatment adherence of people living with HIV/AIDS

Ana Cristina de Oliveira e Silva
Renata Karina Reis
Jordana Almeida Nogueira
Elucir Gir

Objectives: to assess the quality of life of people living with HIV/AIDS and verify its association with clinical characteristics and treatment adherence. Method: cross-sectional study conducted in a hospital in the state of Paraiba, Brazil. A questionnaire was used to collect socio-demographic and clinical data. The quality of life scale proposed by the World Health Organization and a questionnaire to measure treatment adherence were used. Results: of the 314 interviewees, 190 (60.5%) were male, aged 43 years on average, 121 (38.5%) had attended up to five years of schooling, 108 (34.4%) received up to two times the minimum wage, and 112 (35.7%) were on sick leave. In regard to clinical variables, individuals with an undetectable viral load scored higher in all the domains concerning quality of life, with statistically significant differences in three domains. Regarding treatment adherence, 235 (73.8%) presented poor adherence and those who strictly adhered to treatment obtained better scores in quality of life. The results show that quality of life is better among individuals adherent to ART. Supporting people to adhere to the antiretroviral treatment should be a persistent task of healthcare workers and other people participating in the treatment, such as family members and friends.

Descriptors: VHI; Acquired Immunodeficiency Syndrome; Quality of Life; Medication Adherence.

1 Paper extracted from doctoral dissertation "Quality of life of people living with HIV/AIDS and its association with clinic, psychosocial characteristics and adhesion to the treatment", presented to Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
2 PhD, Adjunct Professor, Departamento de Enfermagem Clínica, Universidade Federal da Paraíba, Paraíba, PB, Brazil.
3 PhD, Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
4 PhD, Full Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
Introduction

The impact of the antiretroviral therapy (ART) on people with HIV/AIDS contributed to a decrease in mortality or HIV/AIDS-related illnesses among infected people\(^\text{1}\). The number of AIDS-related deaths among adults and children decreased 29% since 2005. A decrease of 37% of AIDS-related deaths was observed in the last decade in Latin America\(^\text{2}\). This decrease in deaths is certainly a result of therapeutic support, which in addition to prolonging survival, also improves quality of life\(^\text{3}\).

Treatment adherence, psychological changes and clinical characteristics are factors directly associated with the quality of life (QoL) of people living with HIV/AIDS. Consequently, there is a search not only for preventive and control methods, but also for strategies that facilitate and improve the quality of life of HIV/AIDS patients. Coping with HIV/AIDS means facing situations that can decrease or limit quality of life\(^\text{1}\).

Health conditions, housing, safety and social relationships are factors that affect the quality of life of people living with HIV/AIDS in different respects. Quality of life is one of the terms with the highest multifactor expression, which justifies its many definitions. In this study, we opted for the definition of quality of life (QoL) proposed by the World Health Organization (WHO): “individuals’ perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns”\(^\text{3-4}\).

In this context, the quality of life of people living with HIV/AIDS and its relationship with ART became an object of study. Many studies assess the QoL of these people, however, those addressing the relationship of QoL and ART are rare. Hence, this study’s objective was to assess the quality of life of people living with HIV/AIDS and its association with clinical factors and adherence to antiretroviral therapy.

Method

This analytical, cross-sectional study was conducted in a referral hospital for infectious diseases located in João Pessoa, Paraíba, Brazil.

This study included a convenience sample composed of 314 people living with HIV/AIDS. The participants were selected using the feasibility criterion on days care was provided in the referral hospital. The selection criteria included: living with HIV/AIDS, receiving ART for at least three months, and residing in the state of Paraíba, since many of this hospital’s patients are from other states. Data were collected over a period of four months (December 2012 to March 2013) by properly-trained research assistants. The study was approved by the Institutional Review Board at the Federal University of Paraíba (Protocol No. 0405/12) and all the participants signed free and informed consent forms.

A semi-structured questionnaire was used to collect socio-demographic and clinical information. The WHOQOL-HIV Bref\(^\text{5}\) was used to assess Quality of Life. This instrument was composed of 31 items, divided into six domains: physical, psychological, social relationships, environments, level of independence, and religiosity\(^\text{4}\).

The CEAT-VIH instrument (Cuestionario para la Evaluación de la Adhesión al Tratamiento Antirretroviral en Personas con Infección por VIH y Sida) was used to collect data related to adherence to ART. This instrument is composed of 20 items divided into two dimensions: treatment adherence and factors influencing treatment adherence\(^\text{6}\). The minimum score is 17 and the maximum score is 89. In this study, the minimum score was 52 and the maximum was 88. In accordance with the analysis proposed by Remor\(^\text{6}\), the following percentages (PC) were established for the questionnaire global score obtained by the sample: PC ≥ 85 indicates strict adherence (good); 50 ≤ PC < 85 indicates poor adherence (difficulty complying with the treatment); PC ≤ 49 indicate no adherence. The scale’s classification was used to compute the scores of each item of the WHOQOL HIV Bref. The internal consistency for the instrument domains was computed according to Cronbach’s coefficient of reliability.

Results

A total of 314 people living with HIV/AIDS participated in the study: 190 (60.5%) men and 124 (39.5%) women, aged 43 years old on average; ages ranged from 21 to 70 years old. Most participants (110/ 35.0%) were aged between 30 and 39 years old. In regard to education, 193 (61.4%) participants attended up to ten years of schooling, while individuals (121/ 38.5%) who attended from one to five years of schooling predominated. Most participants, 190...
No significant differences were found in the WHOQOL HIV Bref regarding the counting of CD4 T lymphocytes. This study found significant differences in the association between viral load and the psychological, level of independence, and environment domains. Higher scores in all the QoL domains were identified among individuals with a viral load below 50 copies per ml.

As for the presence of diseases or comorbidities in association with QoL domains, no significant differences were found, though significant association was found in regard to the psychological domain and previous diseases. The clinical variable “use of antiretroviral” did not present significant difference in the QoL domains, according to the WHOQOL HIV Bref.

When the average scores of QoL were analyzed in regard to therapeutic adherence (Table 4), we verified that the individuals classified as “non-adherent” presented the worst scores in all the QoL domains. Table 4 presented statistically significant results for the domains: physical, psychological, social relationships, religion, and the assessment using the CEAT.

Table 1 – Distribution of people living with HIV/AIDS according to socio-demographic variables, João Pessoa-PB, Brazil, 2012 and 2013

| Variables       | Category          | No. of individuals (n) | Percentage (%) |
|-----------------|-------------------|------------------------|----------------|
| Sex             | Male              | 190                    | 60.5           |
|                 | Female            | 124                    | 39.5           |
| Age (years)     | 20 to 29          | 25                     | 8.0            |
|                 | 30 to 39          | 110                    | 35.0           |
|                 | 40 to 49          | 92                     | 29.3           |
|                 | 50 to 59          | 64                     | 20.4           |
|                 | 60 to 70          | 23                     | 7.3            |
| Race            | Mixed             | 114                    | 36.3           |
|                 | Not mixed         | 200                    | 63.7           |
| Education       | None              | 27                     | 8.6            |
| (years of schooling) | 1 to 5 years  | 121                    | 38.5           |
|                 | 6 to 10 years     | 72                     | 22.9           |
|                 | 11 to 15 years    | 74                     | 23.6           |
|                 | More than 15 years| 20                     | 6.4            |
| Religion        | Catholic          | 190                    | 60.5           |
|                 | Non-Catholic      | 102                    | 32.5           |
|                 | No religion       | 22                     | 7.0            |
| Income (minimum wage-MW)* | Less than 1 times the MW | 118 | 37.6 |
|                 | From 1 to 2 times the MW | 108 | 34.4 |
|                 | More than 2 times the MW | 88  | 28.0 |
| Occupation      | Employed          | 74                     | 23.6           |
|                 | Retired           | 78                     | 24.8           |
|                 | Sick leave        | 112                    | 35.7           |
|                 | Unemployed        | 50                     | 15.9           |
|                 | Total             | 314                    | 100            |

* Minimum wage current at the time of data collection was R$ 622.00/mo.
Table 2 – Distribution of people living with HIV/AIDS according to clinical variables, João Pessoa-PB, Brazil, 2012 and 2013

| Variables                  | Category          | No. of individuals (n) | Percentage (%) |
|----------------------------|-------------------|------------------------|----------------|
| **Exposure to HIV**        |                   |                        |                |
|                            | Sexual            | 251                    | 79.9           |
|                            | Vertical transmission | 3                   | 1.0            |
|                            | Blood             | 6                      | 1.8            |
|                            | Others            | 54                     | 17.2           |
| **Time since HIV diagnosis** |                   |                        |                |
|                           | 0 to 5 years      | 124                    | 39.5           |
|                           | 6 to 10 years     | 98                     | 31.2           |
|                           | 11 to 15 years    | 78                     | 24.8           |
|                           | More than 15 years| 14                     | 4.5            |
| **Viral load (copies per ml)** |                   |                        |                |
|                           | < 50 (undetectable) | 248                  | 79.0           |
|                           | 50 to 100,000     | 59                     | 18.8           |
|                           | 100,001 to 500,000| 6                    | 1.9            |
|                           | > 500,001         | 1                      | 0.3            |
| **CD4 T cells (amount of lymphocytes cells)** |                 |                        |                |
|                           | < 200 cells/mm³   | 30                     | 9.6            |
|                           | 200 to 350 cells/mm³ | 64                  | 20.4           |
|                           | > 350 cells/mm³   | 220                    | 70.1           |
| **Total**                |                   | 314                    | 100            |

Table 3 – Distribution of scores of the WHOQOL- HIV Bref domains according to clinical variables of people living with HIV/AIDS, João Pessoa-PB, Brazil, 2012 and 2013

| Clinical variables                  | WHOQOL HIV Bref domains | Physical | Psychological | Level of independence | Social relationships | Environment | Spirituality /Religion |
|------------------------------------|-------------------------|----------|---------------|-----------------------|---------------------|-------------|-----------------------|
| Time since diagnosis               |                         | 67.7 (18.9) | 70.2 (13.1)  | 60.6 (15.0)           | 65.8 (17.5)         | 61.7 (15.1) | 73.5 (21.2)           |
|                                    | 3 months to 5 years     | 67.9 (20.8) | 69.1 (16.7)  | 60.7 (17.2)           | 66.2 (20.4)         | 60.6 (15.3) | 69.6 (23.2)           |
|                                    | 6 to 10 years           | 65.8 (20.9) | 70.3 (16.6)  | 63.6 (14.8)           | 66.6 (18.9)         | 64.2 (14.7) | 73.8 (21.5)           |
|                                    | 11 years or more        | 0.804     | 0.858         | 0.259                 | 0.855               | 0.327       | 0.376                 |
| **CD4 T (cell/mm³)**               | < 200                   | 69.8 (21.7) | 67.0 (18.0)  | 56.5 (16.5)           | 66.3 (23.0)         | 57.8 (17.2) | 76.0 (21.1)           |
|                                    | 200 - 350               | 68.1 (20.0) | 70.9 (15.2)  | 62.9 (17.6)           | 66.4 (17.9)         | 63.5 (13.0) | 71.5 (23.2)           |
|                                    | > 350                   | 66.6 (19.9) | 70.0 (15.0)  | 61.8 (14.9)           | 66.1 (18.5)         | 62.3 (15.3) | 72.2 (21.7)           |
| **Viral load (copies per mL)**     | <50 copies per ml       | 68.0 (20.1) | 71.2 (15.0)  | 62.4 (15.5)           | 67.0 (18.4)         | 63.3 (15.3) | 73.3 (21.5)           |
|                                    | ≥50 copies per ml       | 64.4 (19.8) | 64.9 (15.7)  | 58.0 (16.0)           | 62.8 (19.9)         | 57.7 (13.5) | 68.9 (23.3)           |
| **Presence of another disease**    | No                      | 67.2 (20.1) | 70.0 (15.4)  | 61.5 (15.8)           | 66.1 (18.8)         | 62.0 (15.2) | 72.4 (22.2)           |
|                                    | Yes                     | 68.8 (19.8) | 63.6 (10.3)  | 61.6 (9.8)            | 67.0 (19.0)         | 65.2 (10.4) | 72.3 (9.4)            |
| **Previous diseases**              | no                      | 67.8 (19.9) | 70.7 (14.8)  | 61.8 (15.7)           | 66.8 (18.8)         | 62.0 (15.3) | 72.6 (22.2)           |
|                                    | yes                     | 61.5 (21.4) | 62.5 (18.2)  | 59.0 (14.8)           | 60.2 (18.0)         | 62.9 (13.6) | 70.2 (19.7)           |
| **Use of antiretroviral (months)** | Up to 60                | 68.3 (18.3) | 71.0 (12.9)  | 60.4 (14.4)           | 66.6 (17.8)         | 61.5 (15.2) | 72.9 (21.2)           |
|                                    | 61 to 120               | 67.7 (22.9) | 69.2 (17.7)  | 61.7 (17.3)           | 65.1 (19.9)         | 62.2 (15.7) | 71.5 (24.6)           |
|                                    | > 120                   | 65.1 (19.6) | 68.8 (16.1)  | 63.1 (15.6)           | 66.5 (19.2)         | 63.0 (14.4) | 72.6 (20.3)           |
| **Total**                          |                         | 0.114     | 0.004         | 0.033                 | 0.113               | 0.009†       | 0.163†               |

*Kruskal-Wallis test (comparison of three or more independent groups).
†Mann-Whitney test (comparison of two independent samples).
Significant results: (‡) p-value< 0.01 and (§) p-value< 0.05

www.eerp.usp.br/rlae
Discussion

The socio-demographic characterization found among this study’s participants is in agreement with the profile of the HIV/AIDS epidemic in Brazil: men above older than 30 years old, with a low level of education and income, who were infected with HIV/AIDS through sexual transmission(2).

Changes in the profile of people infected with HIV have drawn attention. The ratio of cases between men and women decreased in all age groups(7). Even though the highest incidence of the disease is still observed among male individuals, recent studies show predominance among female individuals. Women are predominant in studies conducted in the South of India(8) and in the United States(9).

Regarding clinical variables observed in this study, for time since diagnosis, the highest number of individuals (124/39.5%) was among those who became aware of their HIV-positive status less than five years ago. Most participants presented good clinical parameters concerning viral load, i.e., undetectable and with a high number of CD4 T cells. The individuals in this study with undetectable viral load scored higher in all the QoL domains. Increased viral load aggravates the individual’s clinical condition, worsening symptoms and increasing the likelihood of hospitalization, consequently decreasing QoL(10). Early diagnosis is one of the aspects linked to a favorable prognosis for HIV/AIDS. Being aware of one’s serological status early on enables appropriate interventions and favors adherence to ART(11).

The results show that all the individuals scored well in the QoL domains according to clinical variables, especially in the psychological and spirituality domains, while the lowest scores were obtained in the level of independence and environment domains. The environment domain presented the lowest score in comparison to the other QoL domains in studies conducted in Brazil: Rondônia(12), Santa Catarina(13), in São Paulo(14) and in Porto Alegre(5).

One study developed in India reports that the scores obtained in QoL domains were higher in regard to the environment domain and lower in the domain concerning spirituality(8). The inverse was observed in this study. Spirituality was the domain with the highest score. Religion, spirituality, and beliefs represent a search for meaning in life, a search for responses to why and for what purpose individuals face stressful and difficult situations, which are considered valid aspects for improved QoL(15).

Spirituality provides support in times of distress, when there is social isolation and distance from the
family. Religion is an important aspect providing meaning and order to life, suffering and distress, a result also found in another study\(^\text{(8,16)}\). An investigation conducted in Ribeirão Preto, SP, Brazil with individuals co-infected with tuberculosis and HIV/AIDS reports that the spirituality domains scored higher than the other domains\(^\text{(17)}\).

The total score obtained on the CEAT in this study was significantly correlated with the physical, psychological, social relationships, and spirituality/religion domains. Low scores obtained in the physical domain may be associated with clinical conditions, viral immunosuppression or lack of ART\(^\text{(17)}\).

Non-adherence to therapy, particularly among people living with HIV/AIDS, is a problem of greater magnitude. The consequences of patients’ lack of adherence affect not only the non-adherent individual but also lead to a series of problems that may reach the population in general. Viral suppression, decreased contamination, minimization of opportunistic infections, and reduced resistance to antiretroviral agents depend on therapy adherence\(^\text{(18)}\).

Most of the studied sample present “poor adherence” and those classified as “non-adherent” obtained the lowest scores in all the QoL domains. The impact of non-adherence to ART on QoL was observed in this study. Given the changes in mortality and morbidity, studies show the positive impact of adherence to ART on QoL\(^\text{(18)}\).

It is known that adherence to ART improves clinical results, delays the progression of the disease, which in theory, should improve quality of life\(^\text{(18)}\). One longitudinal study reports that adherence to ART is associated with improved quality of life\(^\text{(19)}\). Cross-sectional studies also identified associations between QoL and adherence to ART\(^\text{(10,20)}\).

When assessing the quality of life of individuals with HIV/AIDS and its association with ART, one needs to identify the individual’s clinical characteristics and which phase of the infection the individual is experiencing: the asymptomatic, symptomatic or HIV/AIDS last stage\(^\text{(21)}\).

Adherence to antiretroviral treatment may cause side effects in the short run (nausea and vomiting) and in the long run (lipodystrophy and dyslipidemia), impacting quality of life. One study reports no significant difference in the domains of QoL in association with the use of antiretroviral agents, but found significant difference in the overall assessment of health with the presence of adverse effects of medications\(^\text{(21)}\).

The relationship between adherence to ART and quality of life is reciprocal. The quality of life of people living with HIV/AIDS may be influenced by adherence to ART. In this context, it is imperative to understand antiretroviral therapy in order to maximize its benefits and minimize its adverse effects\(^\text{(21)}\).

Most of the participants in this study were asymptomatic with undetectable viral load (< 50 copies per ml). It can be inferred that these clinical characteristics influence adherence to ART and, consequently, influence the QoL of individuals because the absence of symptoms combined with the presence of undesirable side effects, as reported by another study, are factors that hinder adherence to therapy\(^\text{(22)}\).

One limitation of this study is the cross-sectional methodological design. Despite this limitation, the results indicate the need to assess the influence of ART on QoL in this specific population.

**Conclusion**

The quality of life of the studied population according to the WHOQOL HIV Bref was associated with clinical variables and adherence to antiretroviral therapy. Regarding the clinical variables, it is important to note that individuals with viral load below 50 copies per ml obtained the highest scores in all the QoL domains. As for adherence to antiretroviral therapy, individuals classified as “non-adherent” obtained the lowest scores in all the QoL domains.

Adherence to antiretroviral therapy is a positive factor in quality of life, especially because it improves immunity, controls viral load and delays the progression of the disease. Despite these benefits, many people living with HIV/AIDS have difficulty adhering to the therapy. Such difficulties are not only related to the clinical repercussions of the treatment but also due to difficulties accessing the service, and consequently, accessing medications.

In this sense, we suggest there is a need to monitor the ART adherence of people living with HIV/AIDS based on the understanding that adherence is a continuous process that mainly involves the family and healthcare workers. In some situations, non-adherence results from the family and the healthcare workers themselves abandoning the patient.

**References**

1. Brito AM, Szwarcwald CL, Castilho EA. Fatores associados à interrupção de tratamento antirretroviral em adultos com AIDS. Rev Assoc Med Bras. 2006;52(2):86-92.
2. UNAIDS. Joint United Nations Programme on HIV/AIDS. Global Report. AIDS by the numbers. Geneva: Joint United Nations Programme on HIV/AIDS; 2013. [acesso 2 set 2014]. Disponível em: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pdf
3. UNAIDS. Programa Conjunto das Nações Unidas sobre HIV/AIDS. AIDS. Epidemic update. Geneva, UNAIDS; 2012. [acesso 5 out 2013]. Disponível em: http://www.unAids.org/hivdata2009.

4. WHO - World Health Organization. Contry protocol for developing the WHO quality of life (WHOQOL): HIV/AIDS module. Genebra; 1997.

5. Zimpel RR, Fleck MPA. Quality of life in HIV-positive Brazilians: application and validation of the WHOQOL-HIV, Brazilian version. AIDS Care. 2007;19(7):223-30.

6. Remor E. Systematic Review of the Psychometric Properties of the Questionnaire to Evaluate the Adherence to HIV Therapy (CEAT-VIH). Patient. 2013;6:61-73.

7. Ministério da Saúde (BR). Boletim epidemiológico AIDS – DST; 2013. [acesso 26 maio 2014]. Disponível em: http://www.aids.gov.br/sites/default/files/anexos/publicacao/2013/55559/_p_boletim_2013.

8. Chandra PS, Gandhi C, Satishchandra P, Kamat A, Desai A, Ravi V, et al. Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads – a study from South India. Qual Life Res. 2006;15:597-605.

9. Bayliss M, Rendas-Bawm R, White MK, Marish M, Byorner J, Tunis SL, et al. Health-related quality of life (HRQL) for individuals with self-reported chronic physicaland/or mental health conditions: panel survey of an adult sample in the United States. Health Qual Life Outcomes. 2012;10:154.

10. Gaspar J, Reis RK, Pereira FMV, Neves LAS, Castrighini CC, Gir E. Qualidade de vida de mulheres vivendo com o HIV/AIDS de um município do interior paulista. Rev Esc Enferm USP. 2011;45(1):230-6.

11. Vyankandondera J, Mitchell K, Asiimwe-Kateeira B, Boer K, Mutwa P, Balinda JP, et al. Antiretroviral therapy drug adherence in Rwanda: Perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care. 2013;25(12):1504-12.

12. Nascimento JS. Qualidade de vida: percepções de adultos com AIDS no interior de Rondônia. [acesso 20 mar. 2013]. Disponível em: http://repositorio.bce.unb.br/bitstream/10482/2506/1/2006_Janice%20Santana%20do%20Nascimento.pdf.

13. Silva J, Bunn K, Bertoni RF, Neves AO, Traebert J. Quality of life of people living with HIV. AIDS Care. 2013;25(1):71-6.

14. Santos ECM, França I Jr, Lopes F. Qualidade de vida de pessoas vivendo com HIV/AIDS em São Paulo. Rev Saúde Pública. 2007; 41(Suppl 2):64-71.

15. Peterson M, Webb D. Religion and spirituality in quality of life studies. Appl. Res. In Quality of Life. 2006;1:107-16.

16. Reis AC, Lencastre L, Guerra MP, Remor E. Relação entre sintomatologia psicopatológica, adesão ao tratamento e qualidade de vida na infecção HIV/AIDS. Psicologia: Reflexão Crítica. 2010;23(3):420-9.

17. Neves LAS, Canini SRM, Reis RK, Santos CB, Gir E. AIDS e tuberculose: a coinfecção vista pela perspectiva da qualidade de vida dos indivíduos. Rev Esc Enferm USP. 2012;46(3):704-10.

18. Penedo FJ, Gonzalez JS, Dahn JR, Antoni M, Malow R, Costa P, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. Journal of Psychosomatic Research. 2003 Mar;S4(3):271-8.

19. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17(1):10-22.

20. Margalho R, Quakinin S, Canavarro MC. Adesão à HAART, Qualidade de vida e sintomatologia psicopatológica em doentes infectados pelo VIH/SIDA. Acta Med Port. 2011;24(S2):539-48.

21. Souza FG, Külkamp IC, Galato D. Avaliação da qualidade de vida em um grupo de portadores de HIV. DST - J Bras Doenças Sex Transm. 2009;21(2):53-5.

22. Goujard C, Bernard N, Sohier N, Sohier N, Peyramond D, Lançon F, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34(2):191-4.